共 50 条
Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: An open-label trial
被引:35
|作者:
Nagata, Ken
[1
]
Yokoyama, Eriko
[2
]
Yamazaki, Takashi
[1
]
Takano, Daiki
[1
]
Maeda, Tetsuya
[1
]
Takahashi, Satoshi
[3
]
Terayama, Yasuo
[3
]
机构:
[1] Res Inst Brain & Blood Vessels, Dept Neurol, Akita 0100874, Japan
[2] Akita Prefectural Ctr Rehabil & Psychiat Med, Dept Rehabil, Daisen, Japan
[3] Iwate Med Univ, Dept Neurol, Morioka, Iwate 020, Japan
关键词:
Yokukansan;
Behavioral and psychological symptoms of dementia;
Vascular dementia;
TRADITIONAL JAPANESE MEDICINE;
YI-GAN-SAN;
ALZHEIMER-DISEASE;
SEROTONIN TRANSPORTER;
AGGRESSIVE-BEHAVIOR;
DIAGNOSTIC-CRITERIA;
RECEPTOR-BINDING;
POLYMORPHISMS;
PSYCHOPATHOLOGY;
DISTURBANCE;
D O I:
10.1016/j.phymed.2012.02.008
中图分类号:
Q94 [植物学];
学科分类号:
071001 ;
摘要:
Previous clinical trials suggest that the traditional Japanese medicine yokukansan has beneficial effects on the behavioral and psychological symptoms of dementia (BPSD). The present study was conducted to elucidate the efficacy of yokukansan on BPSD in patients with vascular dementia. Thirteen Japanese patients (9 men and 4 women) who were diagnosed as having vascular dementia (VaD) according to the diagnostic criteria of NINDS-AIREN were subjected to the open-label clinical trial in which yokukansan (7.5g/day) has been given for 4 weeks. Their mean age was 71.2 +/- 6.5 years. The BPSD was evaluated using the Neuropsychiatric Inventory (NPI), cognitive function was evaluated by the Mini-Mental State Examination (MMSE), the activities of daily living was evaluated by Barthel index (BI) and Disability Assessment for Dementia (DAD), and the extrapyramidal signs were evaluated by United Parkinson's Disease Rating Scale (UPDRS). The mean NPI was 33.0 +/- 17.3 and 23.6 +/- 13.9 for the baseline and after treatment, respectively. It was significantly improved after treatment (p < 0.05). In the NPI-subcategories, there was a significant improvement in agitation and disinhibition after the treatment. There was no significant change in MMSE, BI, DAD or UPDRS before and after the treatment. There was no adverse effect during the treatment period. The present results suggest that yokukansan is beneficial for the treatment of BPSD in VaD patients. (C) 2012 Elsevier GmbH. All rights reserved.
引用
收藏
页码:524 / 528
页数:5
相关论文